Standardized Prevalence Ratios for Chronic Hepatitis C Virus Infection Among Adult Japanese Hemodialysis Patients

Access this Article

Search this Article

Author(s)

    • OHSAWA Masaki
    • Department of Hygiene and Preventive Medicine, Iwate Medical University
    • KATO Karen
    • Department of Urology, Iwate Medical University
    • ITAI Kazuyoshi
    • Department of Hygiene and Preventive Medicine, Iwate Medical University
    • TANNO Kozo
    • Department of Hygiene and Preventive Medicine, Iwate Medical University
    • OKAYAMA Akira
    • The First Institute of Health Service, Japan Anti-Tuberculosis Association
    • ABE Koichi
    • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University
    • SUZUKI Kazuyuki
    • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University
    • NAKAMURA Motoyuki
    • Division of Cardiovascular Medicine, Nephrology and Endocrinology, Department of Internal Medicine, Iwate Medical University
    • ONODA Toshiyuki
    • Department of Hygiene and Preventive Medicine, Iwate Medical University
    • SAKATA Kiyomi
    • Department of Hygiene and Preventive Medicine, Iwate Medical University
    • AKIBA Takashi
    • Division of Blood Purification, Kidney Center, Tokyo Women's Medical University

Abstract

<b>Background: </b>Many studies have estimated the prevalence of anti-hepatitis C virus (HCV) antibody among hemodialysis (HD) patients; however, the prevalence of HCV core antigen—which indicates the presence of chronic HCV infection—is not known.<BR><b>Methods: </b>Standardized prevalence ratios (SPRs) for anti-HCV antibody and HCV core antigen among HD patients (<i>n</i> = 1214) were calculated on the basis of data from the general population (<i>n</i> = 22 472) living in the same area.<BR><b>Results: </b>The prevalences of anti-HCV antibody and HCV core antigen were 12.5% and 7.8%, respectively, in male hemodialysis patients, and 8.5% and 4.1% in female hemodialysis patients. The SPRs (95% confidence interval) for anti-HCV antibody and HCV core antigen were 8.39 (6.72–10.1) and 12.9 (9.66–16.1), respectively, in males, and 5.42 (3.67–7.17) and 8.77 (4.72–12.8) in females.<BR><b>Conclusions: </b>The prevalences of chronic HCV infection among male and female HD patients were 13-fold and 9-fold, respectively, those of the population-based controls. Further studies should therefore be conducted to determine the extent of chronic HCV infection among HD patients in other populations and to determine whether chronic HCV infection contributes to increased mortality in HD patients.

Journal

  • Journal of Epidemiology

    Journal of Epidemiology 20(1), 30-39, 2010-01-01

    Japan Epidemiological Association

References:  42

Cited by:  2

Codes

  • NII Article ID (NAID)
    10026251297
  • NII NACSIS-CAT ID (NCID)
    AA10952696
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    09175040
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top